UA30304U - Процесс оценки развития атерогенных осложнений при матеболическом синдроме - Google Patents
Процесс оценки развития атерогенных осложнений при матеболическом синдроме Download PDFInfo
- Publication number
- UA30304U UA30304U UAU200710804U UAU200710804U UA30304U UA 30304 U UA30304 U UA 30304U UA U200710804 U UAU200710804 U UA U200710804U UA U200710804 U UAU200710804 U UA U200710804U UA 30304 U UA30304 U UA 30304U
- Authority
- UA
- Ukraine
- Prior art keywords
- metabolic
- coefficients
- development
- complications
- atherogenic
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 44
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 44
- 230000000923 atherogenic effect Effects 0.000 title claims abstract description 21
- 238000011161 development Methods 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 15
- 230000008569 process Effects 0.000 title claims abstract description 5
- 230000002503 metabolic effect Effects 0.000 claims abstract description 37
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 25
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 25
- 102000015779 HDL Lipoproteins Human genes 0.000 claims description 17
- 210000002381 plasma Anatomy 0.000 claims description 6
- 230000037356 lipid metabolism Effects 0.000 claims description 5
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 4
- 108010010234 HDL Lipoproteins Proteins 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 150000002632 lipids Chemical group 0.000 abstract description 11
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 238000011156 evaluation Methods 0.000 abstract 1
- 238000011835 investigation Methods 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 description 17
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 11
- 206010061216 Infarction Diseases 0.000 description 10
- 208000010125 myocardial infarction Diseases 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 238000002565 electrocardiography Methods 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 206010003119 arrhythmia Diseases 0.000 description 7
- 230000006793 arrhythmia Effects 0.000 description 7
- 206010002383 Angina Pectoris Diseases 0.000 description 6
- 206010020772 Hypertension Diseases 0.000 description 6
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 6
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 6
- 230000036772 blood pressure Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000035150 Hypercholesterolemia Diseases 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 208000004434 Calcinosis Diseases 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 208000007718 Stable Angina Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000004611 Abdominal Obesity Diseases 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000014882 Carotid artery disease Diseases 0.000 description 3
- 206010065941 Central obesity Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 3
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 3
- 208000037849 arterial hypertension Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000002308 calcification Effects 0.000 description 3
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 210000004351 coronary vessel Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000006575 hypertriglyceridemia Diseases 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 230000000737 periodic effect Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000001020 rhythmical effect Effects 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 210000001562 sternum Anatomy 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 206010003658 Atrial Fibrillation Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 2
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 2
- 238000011872 anthropometric measurement Methods 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000009863 secondary prevention Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- TUZYXOIXSAXUGO-JFBQIPGGSA-N (3r,5r)-7-[(2s,6s,8s,8ar)-6-hydroxy-2-methyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C1=C[C@H](C)C(CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-JFBQIPGGSA-N 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 101000843477 Escherichia coli (strain K12) RNA-binding protein Hfq Proteins 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000009785 Inferior Wall Myocardial Infarction Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- 208000007888 Sinus Tachycardia Diseases 0.000 description 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 1
- 208000031353 Systolic Murmurs Diseases 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002555 auscultation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000013171 endarterectomy Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 201000009526 inferior myocardial infarction Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000037822 retinal angiopathy Diseases 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 210000002186 septum of brain Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 150000005671 trienes Chemical class 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Процесс оценки развития атерогенных осложнений при метаболическом синдроме состоит в том, что проводят биохимические исследования плазмы венозной крови натощак, определяют показатели липидного обмена, оценивают выраженность атерогенности метаболической дислипидемии. Для ее оценки определяют и совместно оценивают коэффициенты метаболической дислипидемии (К1, К2) в виде соотношений триглицеридов и общего холестерина (К1 = ТГ/ЗХС) и триглицеридов и холестерина липопротеидов высокой плотности (К2 = ТГ/ ХС ЛПВЩ), при значении этих коэффициентов выше или ниже 0,34 и 1,5 соответственно судят о развитии сердечно-сосудистых осложнений метаболического синдрома и неблагоприятный ход заболевания.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200710804U UA30304U (ru) | 2007-10-01 | 2007-10-01 | Процесс оценки развития атерогенных осложнений при матеболическом синдроме |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU200710804U UA30304U (ru) | 2007-10-01 | 2007-10-01 | Процесс оценки развития атерогенных осложнений при матеболическом синдроме |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA30304U true UA30304U (ru) | 2008-02-25 |
Family
ID=39817892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU200710804U UA30304U (ru) | 2007-10-01 | 2007-10-01 | Процесс оценки развития атерогенных осложнений при матеболическом синдроме |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA30304U (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2521322C1 (ru) * | 2013-02-12 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ оценки прогрессирования атерогенности при ишемической болезни сердца |
| RU2721687C1 (ru) * | 2019-06-13 | 2020-05-21 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования возможных тромбогенных осложнений при липидемии атерогенного генеза и клиническом диагнозе стенокардия напряжения разных функциональных классов |
-
2007
- 2007-10-01 UA UAU200710804U patent/UA30304U/ru unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2521322C1 (ru) * | 2013-02-12 | 2014-06-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" Сибирского отделения Российской академии медицинских наук | Способ оценки прогрессирования атерогенности при ишемической болезни сердца |
| RU2721687C1 (ru) * | 2019-06-13 | 2020-05-21 | Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) | Способ прогнозирования возможных тромбогенных осложнений при липидемии атерогенного генеза и клиническом диагнозе стенокардия напряжения разных функциональных классов |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jones et al. | Natural history of coronary artery disease. | |
| Yetman et al. | Long-term outcome in patients with Marfan syndrome: is aortic dissection the only cause of sudden death? | |
| Ghorayeb et al. | The Brazilian society of cardiology and Brazilian society of exercise and sports medicine updated guidelines for sports and exercise cardiology-2019 | |
| RU2570089C1 (ru) | Способ определения риска смерти и нефатальных сердечно-сосудистых осложнений у больных хронической ишемической болезнью сердца в отдаленном периоде | |
| UA30304U (ru) | Процесс оценки развития атерогенных осложнений при матеболическом синдроме | |
| Evrengul et al. | Aortic stiffness and flow-mediated dilatation in normotensive offspring of parents with hypertension | |
| Nikolić et al. | Does the myocardial bridge protect the coronary from atherosclerosis? A comparison between the branches of the dual-left anterior descending coronary artery type 3: an autopsy study | |
| Poirier | Targeting abdominal obesity in cardiology: can we be effective? | |
| RU2731887C1 (ru) | Способ диагностики эндогенного воспаления у больных саркоидозом по показателю активности липоидоза | |
| Vasamreddy et al. | Cardiovascular disease in athletes | |
| Nikolić et al. | The Influence of Professional Sport on Changes in the Athlete’s Cardiovascular System After the end of Career | |
| Thompson | Exercise and the heart: the Good, the Bad, and the Ugly | |
| Samir | Long-term outcomes of catheter ablation pulmonary veins on example of a clinical case patient with paroxysmal atrial fibrillation | |
| Ghanem Wisam et al. | Is left ventricular hypertrophy a risk factor in hypertensive patients? | |
| De Ciuceis et al. | Poor concordance between non-invasive and locally invasive techniques of evaluation of microvascular morphology in the detection of hypertrophic remodeling of small resistance arteries | |
| Salvetti et al. | RESISTANT HYPERTENSION IN A GENERAL POPULATION IN NORTHERN ITALY: PREVALENCE, ASSOCIATED CARDIOVASCULAR RISK FACTORS AND TARGET ORGAN DAMAGE: PP. 42.362 | |
| Mizuno et al. | ISH NIA PS 02-04 Urinary Na and K excretion values in outpatients with hypertension compared to patients with other diseases | |
| Kasapis et al. | Sports cardiology | |
| Didigova et al. | PREVALENCE OF HYPERTENSION AND EFFECTIVENESS OF ITS TREATMENT IN CORONARY HEART DISEASE PATIENTS OF NORTH CAUCASUS: PP. 42.363 | |
| Millar et al. | Clinical and Genetic Aspects of Sudden Cardiac Death in the Practice of Sports Medicine | |
| Erbel et al. | The coronary calcium score for risk prediction | |
| Mohr et al. | Football as Medicine against cardiovascular disease | |
| Salvetti et al. | P1. 10: Prevalence of Resistant Hypertension in A General Population in Northern Italy: Associated Cardiovascular Risk Factors and Target Organ Damage | |
| Haukilahti | Sudden cardiac death, cardiac mortality, and morbidity in women: electrocardiographic risk markers | |
| Tamarit-García et al. | HOW TO DETERMINE THE ANKLE BRACHIAL INDEX IN THE INTERNAL MEDICINE OFFICES OF TWO SPANISH HOSPITALS: PP. 42.360 |